Kornimate/medical-research-clean huggingface dataset:
correlation between gut microbiota and radiosensitivity of rectal cancer

Conditions: Locally Advanced Rectal Cancer

Summary: the purpose of this process is to clarify the characteristics of gut microbiota changes in patients with locally advanced rectal cancer undergoing preoperative neoadjuvant treatment, and to identify key bacterial species closely related to sensitivity to radiotherapy. this aims to elucidate the mechanism linking gut microbiome dysbiosis with radiotherapy sensitivity, thereby providing new combined treatment strategies to enhance the efficacy of radiotherapy.

the study is expected to enroll 100 patients with locally advanced rectal cancer, including 50 patients in the radiotherapy-sensitive group and 50 in the radiotherapy-resistant group. each participant will provide stool and blood samples before treatment for subsequent metagenomic and metabolomic sequencing analysis.

Eligibility criteria:
inclusion criteria: 1. patients with late-stage rectal cancer (stages iiib to iv), including those with postoperative recurrence re-staging or those intending to receive neoadjuvant treatment, 2. pathological type is adenocarcinoma, 3. have measurable lesions before radiotherapy or chemotherapy, 4. age between 18 and 75 years, 5. a who performance status (ps) score of 0 to 2, capable of tolerating radiotherapy or chemotherapy, 6. an expected survival period of 6 months or more; 7. able to understand the study and sign the informed consent form. exclusion criteria: 1. patients with severe complications or other malignant diseases. 2. known severe allergic reactions to components of radiotherapy or chemotherapy. 3. significant cardiac, hepatic, renal, or other vital organ dysfunction. 4. pregnant or breastfeeding women. 5. patients unable to comply with study requirements or affected by psychiatric or psychological diseases. 6. participation in other clinical trials recently that could affect the assessment of this study's results.
treatment of transsphicteric fistula-in-ano by method of laser thermoobliteration(filac™).

Conditions: Anal Fistula

Summary: this is a randomized, controlled, parallel study to compare the results of treatment for patients with transsphincteric fistulas-in-ano.

we are planning to eroll 120 patients in this study,the duration of the stady be 3 years. each of two groups will include 60 people. pationts in the first group will be assigned to get treatment of the fistula-in-ano by laser thermo-obliteration (filac™), patietns of the second group will forego monopolar coagulation of the fistulas tract with suturing the internal fistulas opening.

Eligibility criteria:
inclusion criteria: 1. informed consent to the study; 2. patients with high transsphincteric fistula (\>1/3), suprasphincteric fistula whithout abscesses; 3. the presence of a formed fistulous tract \> 2 cm in length. exclusion criteria: 1. suprasphincteric fistula with abscesses or infiltrates; 2. extrasphincteric fistula; 3. length of fistula tract \< 2 cm; 4. the presence of sever scars in the region of internal fistula opening, wide fistula opening \> 5 mm; 5. crohn's fistulae
sop toolkit in diverse practices implemented & tested with re-aim

Conditions: Adult Influenza Vaccinations; Adult PPSV Vaccinations; Adult Tdap/Td Vaccinations

Summary: the purpose of this study is to test whether or not the 4 pillars toolkit increases adult influenza, pneumococcal polysaccharide vaccine (ppsv), tetanus, adult diphtheria and acellular pertussis vaccine (tdap/td) vaccination rates. the vaccines are all fda licensed vaccines and to be used according to national guidelines. the investigators will conduct a randomized cluster trial of this toolkit in diverse primary care practice with electronic medical records (emrs).

this intervention is a two-region, two-year, stratified randomized cluster trial in 24 primary care practices with emrs. these practices will be randomly assigned to be intervention or control sites to test this 4 pillars toolkit intervention package of evidence-based techniques tailored to their practice structure and culture; one set of practices randomized to intervention in year 1 and the other to control. in year 2, the other set of practices will receive the intervention and community controls may be sought. these diverse practices consist of: 18 diverse practices from upmc in western pennsylvania and 6 diverse practices from large community health centers in a pbrn in texas.

Eligibility criteria:
practice staff and adults in enrolled clinical sites inclusion criteria: site inclusion criteria: * 1) an appropriate adult population: e.g., adults aged 50 years and older; * 2) currently using an emr that has prompt ability, such as epiccare; * 3) having and keeping immunization data within this emr patient-level inclusion criteria: * 1) adults (18 years and above) who are active patients of the enrolled practices (e.g., active patients are those with a visit within the last 12 months) * 2) all unvaccinated adults without a contraindication are eligible to receive td/tdap and influenza, regardless of age and at age 65 years or older are eligible for ppsv. exclusion criteria: site exclusion criteria: * 1) consistent sop use for the 3 vaccines being studied or high vaccination rates (e.g., 80%) patient-level exclusion criteria: * 1) those with a true contraindication, following the cdc's guide to contraindications (attached with the us recommended adult immunization schedule), such as prior vaccine anaphylaxis.

Keywords: influenza vaccine ppsv tdap vaccination adult
study on influence of leutinizing hormone (lh) on oocyte maturity

Conditions: Infertility

Summary: 1. leutinizing hormone (lh) has been demonstrated to exert variable physiological actions during menstrual cycle at appropriate plasma levels' 2. in early follicular phase,in the requisite range,lh is known to contribute to maturation of oocyte during transition phase from metaphase-1(m1) to metaphase-2 (m2). 3. if during this transition, appropriate level of lh can be maintained either through the use of gonadotropin releasing hormone (gnrh) antagonist if found excessive or supplementation with exogenous lh, if found deficient, maturation process can be enhanced. 4. further maintenance of suitable combination of recombinant follicle stimulating hormone (rfsh) + rlh can help in realizing higher yield of mature m2 oocytes,with higher probability of establishing clinical pregnancy.

the study is planned to assess whether maintenance of levels of lh through the use of gnrh antagonist would contribute to obtaining mature m2 oocytes so that maximum number of good quality embryo's with potential to implant is obtained. the mature oocytes would be subjected to either standard in-vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi) depending on the status of the male factor. the objective would be to obtain good quality embryo's with implantation potential for fresh embryo transfer and/or subsequent frozen thaw embryo transfer. in both these events, the secondary outcome measures would be establishment of clinical pregnancy by transvaginal ultrasound performed 6 weeks after embryo transfer.

Eligibility criteria:
inclusion criteria: * women aged 18-40 years * primary or secondary infertility * desire to achieve pregnancy * basal fsh \<12 miu/ml * moderate to good ovarian reserve (antimullerian hormone (amh) \>1ng/ml, and/ or antral follicle count (afc)\>8 between both ovaries) * informed written consent from both partners * bmi \<35 kg/mtr.sq. * no genetic abnormality exclusion criteria: * hormonal preparation taken within 3 month prior to recruitment * women with previous poor response to gonadotrophins * history of previous 3 or more miscarriages * women with uncorrected tubal/uterine pathology * women opting for assisted procedures like embryo hatching etc.

Keywords: ivf-et icsi gonadotrophins rfsh rlh cetrorelix leuprolide acetate
linking endotypes and outcomes in pediatric acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: the overall goal of the study is to risk stratify pediatric acute respiratory distress syndrome (ards) patients and to identify sub-phenotypes with shared biology in order to appropriately target therapies in future trials. this is a prospective, multicenter study of 500 intubated children with ards, with planned blood collection within 24 hours of ards onset and subsequent measurement of plasma protein biomarkers and peripheral blood gene expression.

investigators will measure pre-determined biomarkers with known or suspected association with ards severity or outcome. simultaneously, investigators will measure gene expression of peripheral blood. both plasma biomarkers and gene expression profiles will be analyzed using various machine learning techniques, including classification and regression tree, latent class analysis, and hierarchical clustering with the goal of identifying sub-phenotypes of ards. these sub-phenotypes will be examined for association with outcome (primary is 28-day mortality), and explicitly tested for variation in response to exogenous treatments (e.g., corticosteroids).

Eligibility criteria:
inclusion criteria: 1. acute (≤ 7 days of risk factor) respiratory failure requiring invasive mechanical ventilation 2. age \> 44 weeks corrected gestational age and \< 17.5 years 3. invasive mechanical ventilation via endotracheal tube 4. bilateral infiltrates on chest radiograph 5. oxygenation index (oi) ≥ 4; or oxygen saturation index (osi) ≥ 5 on 2 consecutive measurements at least 4 hours apart but \< 24 hours apart 6. invasively ventilated ≤ 7 days before meeting above radiographic and oxygenation criteria exclusion criteria: 1. weight \< 3 kilograms 2. cyanotic congenital heart disease (other than patent foramen ovale (pfo) or patent ductus arteriosus (pda)) 3. tracheostomy at time of screening 4. invasively ventilated for \> 7 days when meet ards criteria above 5. cardiac failure as predominant cause of respiratory failure 6. primary obstructive airway disease (asthma, bronchiolitis) by judgement of clinician as the primary cause of respiratory failure 7. alternative known chronic lung disease as cause of respiratory failure (cystic fibrosis, eosinophilic pneumonia, interstitial pneumonitis, pulmonary hemosiderosis, cryptogenic organizing pneumonia) 8. severe neurologic morbidity not expected to survive \> 72 hours 9. any limitations of care at time of screening 10. previous enrollment in this study

Keywords: acute respiratory distress syndrome ards
comparative efficacy and safety of thalidomide and sulfasalazine in moderate to severe ankylosing spondylitis: a real-world study from bangladesh

Conditions: Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh; Condition ...Moderate to Severe Axial Spondyloarthopathy

Summary: the present study was conducted to determine the comparative efficacy and safety of thalidomide and ssz in moderate to severe cases of ankylosing spondylitis in bangladesh.


Eligibility criteria:
inclusion criteria: * the present study included patients aged \>18 years with inflammatory low back pain fulfilling the modified new york criteria for moderate to severe ankylosing spondylitis. the criteria include radiographic sacroiliitis (at least grade ii bilaterally or grade iii unilaterally) along with clinical signs, such as inflammatory back pain for at least 3 months' duration, limitation of lumbar spine in sagittal and frontal planes, or chest expansion decreased relative to normal values for age and sex exclusion criteria: * exclusion criteria were non-inflammatory back pain or back pain due to inflammatory causes other than as, failure to confirm a washout period of four weeks, those, those who were on dmards, allergy to thalidomide, sulphasalazine, and nsaids, known to have kidney diseases or cardiac disease, active peptic ulcer disease, and pregnancy.
airwave compression therapy to prevent breast cancer-related lymphedema

Conditions: Breast Cancer

Summary: this study aims to explore the effectiveness of early intervention of airwave compression therapy to prevent the occurrence of postoperative breast cancer-related lymphedema(bcrl).

this study aims to explore the effectiveness of early intervention of airwave compression therapy to prevent the occurrence of postoperative breast cancer-related lymphedema (bcrl), hereby improving the quality of life of patients with breast cancer. furthermore, we will perform exploratory analyses to investigate the predictive values of patient plasma cytokines to the occurrence and development of bcrl.

Eligibility criteria:
inclusion criteria: * volunteer to participate in this clinical trial. fully understand and be informed about the study and sign an informed consent form (icf). willing to follow and able to complete all test procedures; * female, ≥18 years old and ≤70 years old at the time of signing the icf; * patients with unilateral breast cancer diagnosed by histopathology or cytology; * no distant metastasis; * to undergo unilateral axillary sentinel lymph node biopsy or unilateral axillary lymph node dissection; * have not received any treatment for arm lymphedema; * no lymphangitis and other infections. exclusion criteria: * breast malignancy derived from other tumors rather than the primary breast cancer; * patients with second primary tumor; * contraindication to airwave compression therapy: acute venous thrombosis; acute inflammatory skin disease; erysipelas; arrhythmia; pulmonary edema; unstable hypertension; people with artificial pacemakers; deep thrombophlebitis; * have a history of mental illness or other reasons can not cooperate with treatment; * embolism, cardiogenic edema, hepatogenic edema and the history of upper limb trauma and other related complications; * patients using any medication that affects fluid or electrolyte balance.

Keywords: breast cancer-related lymphedema airwave compression therapy quality of life
18f-av-1451 high resolution autopsy study

Conditions: Alzheimer's Disease

Summary: the study is designed to examine the relationship between imaging results detected on a 18f-av-1451 pet scan and pathology found at autopsy within six months of imaging.


Eligibility criteria:
inclusion criteria: * projected life expectancy ≤ 6 months exclusion criteria: * primary brain tumor, known metastases to the brain, central nervous system lymphoma * major, focal structural brain lesion * aggressively being treated with life sustaining measures * clinically significant infectious disease * history of risk factors for torsades de pointes or are currently taking medication known to cause qt prolongation * have received or participated in a trial with investigational medications in the past 30 days * females of childbearing potential who are pregnant or not using adequate contraception
impact of nocturnal hypoxemia on glucose in high altitude sleep disordered breathing

Conditions: Sleep-Disordered Breathing; Glucose Intolerance

Summary: sleep disordered breathing is associated with impaired glucose tolerance and incident diabetes. nocturnal hypoxemia is a potential stimulus of glucose intolerance. it is especially severe and highly prevalent in high altitude residents. intervening on nocturnal hypoxemia may therefore improve glucose control and decrease the public health burden in high altitude populations. the objective of this study is to examine the impact of hypoxemia on glucose homeostasis in high altitude residents. the investigators will address this objective by examining the effect of supplemental oxygen on glucose in a randomized cross-over study.


Eligibility criteria:
inclusion criteria: * permanent residents of puno, peru exclusion criteria: * recent travel to low altitude (\<3000 m) * oxygen use * pregnancy * morbid obesity (bmi \> 40 kg/m2) * current smoking * diabetes * other sleep disorders (e.g. circadian rhythm disorder or insomnia) * use of open fires in the home (i.e. for cooking or heat) * chronic mountain sickness (cms) as defined by a daytime oxyhemoglobin saturation \ 10 or excessive erythrocytosis as defined by hemoglobin \>19 g/dl in women or \>21 g/dl in men.
influences of allergic rhinitis and allergen immunotherapy on sars-cov-2 vaccination

Conditions: Allergic Rhinitis; Allergen Immunotherapy; SARS-CoV-2

Summary: the study is designed to assess whether allergic rhinitis and allergen immunotherapy affect the humoral response to sars-cov-2 vaccination in adults. this is a prospective study enrolling a total of approximately 120 subjects, 18-55 years old.

background: allergic rhinitis (ar) is a disorder caused by hypersensitivity of the immune system to harmless allergens in the environment, which represents a global public health problem affecting up to 20-50% of the population. allergen immunotherapy (ait) is the only effective treatment that not only has disease-modifying property but also confers long-term clinical benefit after cessation of treatment for ar patients. vaccination is one of the most powerful interventions for reducing disability and death caused by infectious disease. immunization with the inactivated sars-cov-2 vaccine remains the most effective strategy to combat covid-19 infections. nevertheless, the influences of allergic rhinitis and allergen immunotherapy on sars-cov-2 vaccination are still unknown. objectives: to investigate if ar and ait will influence the humoral response to sars-cov-2 vaccination in adults. design and trial size: this is a prospective study. a total of approximately 120 subjects, 18-55 years old, including 40 healthy subjects, 40 patients with ar without ait, and 40 patients with ar with ait for more than 1 year, will be enrolled in this study. intervention and duration: all of the study participants will be vaccinated with an 2 doses inactivated vaccine against sars-cov-2 (covilo). peripheral blood samples will be collected at baseline (prior to vaccinate), 7 and 30 after first vaccine, and, 7 and 30 after second vaccine. one-month additional data analysis leads to the trial duration of 3 months.

Eligibility criteria:
inclusion criteria: 18-55 years; healthy subjects, patients with ar without ait, or patients with ar with ait for more than 1 year exclusion criteria: 1. who infected with covid-19 previously 2. cannot finish the follow up 3. previous allergic to other vaccines 4. who have had severe immunologic, cardiac, liver or metabolic disease, tumors, allergic diseases, or chronic infection, 5. pregnancy or breastfeeding 6. suffered from airway infection or severe infectious diseases in the past 3 months, prior to this study.
a personalized intervention to manage physiological stress and improve sleep patterns

Conditions: Type 2 Diabetes Mellitus

Summary: globally, type 2 diabetes mellitus (dm) and obesity are considered to be the fastest growing disorders and their prevalence has increased dramatically over the last twenty years. recent studies have shown that about 19% of uae population has been diagnosed with dm and 57% of emirati patients with type 2 dm are obese. optimal glycemic control and weight management involve comprehensive lifestyle approaches including nutrition recommendations and adequate levels of physical activity. however, recent views have suggested that there are other factors, such as sleep deprivation and stress, contribute to development of type 2 dm. taking into account the previous findings, the present study was designed to investigate the effects of a personalized intervention on weight and glycemic control in emirati patients with type 2 dm. the intervention involves assessment and modification of sleep patterns and stress levels.

the present study is a randomized controlled trial which was conducted at rashid centre for diabetes and research (rcdr) in ajman which in one of the seven emirates of the united arab emirates (uae). the study was approved by the research ethics committee of al qassimi clinical research centre, al qassimi hospital (ministry of health, uae). the study population is comprised of emirati individuals (n = 51) who attending rcdr diabetes clinics in a quarterly basis (an initial visit and three follow-up visits per annum). the participants were recruited from rcdr diabetes clinics and through different methods including (i) direct contact (ii) distribution of informative flyers and (iii) phone calls using diamond, an electronic medical database of rcdr patients. the screening process involved 110 emirati patients with t2dm and 51 individuals were eligible to participate in the present trial based on the following inclusion and exclusion criteria. the inclusion criteria were (i) age between 18-60 years (ii) body mass index (bmi \> 25 kg/m2) and (iii) t2dm. the exclusion criteria were (i) age \ 60 years (ii) bmi \< 25 kg/m2) (iii) type 1 dm (iv) diagnosis of atrial fibrillation and/or atrial flutter and/or bundle branch block and (v) heart transplantation. the eligible participants were randomly allocated into an intervention group (n = 26) and or into a control group (n = 25). non-compliance was the main obstacle to maintain the same number of the randomized participants in each group and 19% and 24 % of the participants in the intervention and control group, respectively, did not attend the first visit.

Eligibility criteria:
inclusion criteria: * age between 18-60 years * body mass index (bmi \> 25 kg/m2) * t2dm exclusion criteria: * age \ 60 years * bmi \< 25 kg/m2) * type 1 dm * diagnosis of atrial fibrillation and/or atrial flutter and/or bundle branch block heart transplantation

Keywords: type 2 diabetes, physiological stress, sleep pattern
sofosbuvir, ledipasvir, ribavirin for hepatitis c cirrhotics, genotype 1

Conditions: Hepatitis C; Cirrhosis

Summary: the investigators will treat 50 patients with cirrhosis due to hepatitis c genotype 1, with sofosbuvir 400 mg daily, ledipasvir 90 mg daily and weight-based ribavirin (1000 mg/d if \ 75 kg, divided in two daily doses) for 12 weeks and calculate the sustained viral response rate at 12 weeks.

cirrhosis due to hepatitis c virus (hcv) presents a rather difficult treatment problem as many cannot tolerate interferon, the previous standard of care. the new direct acting antivirals have provided these patients with a new hope. one such combination is sofosbuvir (sof) 400 mg and ledipasvir (ldv) 90 mg given once daily with or without weight-based ribavirin (rbv) for 12 or 24 weeks only for hcv genotype 1 patients. the current recommendation for cirrhotics (genotype 1) is sof/ldv/rbv for 24 weeks but that recommendation is based on the lack of data for shorter periods. in order to evaluate the response rate to the combination of sof/ldv/rbv the investigators decided to treat 50 hcv genotype 1 cirrhotics with this combination for 12 weeks. patients with meld score \> 20 are excluded. the investigators will calculate the sustained viral response rate at 12 weeks (svr12).

Eligibility criteria:
inclusion criteria: * positive qualitative hepatitis c rna polymerase chain reaction assay on two occasions at least 6 months apart exclusion criteria: * renal failure \[estimated glomerular filtration rate (egfr) \< 30 cc/min\], * model or end stage liver disease (meld) score \> 20, * child's class c (score \> 12), * heart rate \< 50/min, * taking amiodarone

Keywords: hepatitis c cirrhosis sofosbuvir ledipasvir ribavirin